bioMérieux S.A.. (1/19/17). "Press Release: bioMérieux – Fourth-Quarter 2016 Business Review". Marcy l’Étoile.

	Organisation	bioMérieux S.A. (Euronext: BIM)
	Group	Mérieux (Group)
	Organisation 2	Biotheranostics Inc.
	Product	in vitro diagnostics (IVD)
	Product 2	FilmArray® PCR test (product series)
	Person	Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)

> Remarkable growth in sales in 2016, up 9.6% like-for-like, lifted by all regions and all strategic lines:
€2,103 million in sales
Up 7.1% as reported

> Strong contribution from the Americas region to Group sales growth

> Success for FilmArray® in molecular biology, with sales at almost €250 million for full-year 2016

> bioMérieux expects contributive operating income before non-recurring items to be slightly above its previous target, moving closer to €300 million

Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux's excellent sales dynamic helped drive organic sales growth of 9.6% and confirms the relevance of our positioning as a specialist in infectious diseases. Given the firm fourth-quarter performance, contributive operating income before non-recurring items should come in slightly higher than our previous estimate. In this favorable environment, the Company will continue to pursue its strategic investments in order to innovate and provide its customers with high value-added medical solutions, making a lasting contribution to improved patient care."

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the twelve months ended December 31, 2016.

SALES

Consolidated sales amounted to €2,103 million in 2016, versus €1,965 million in 2015. Year-on-year organic sales growth (i.e., at constant exchange rates and scope of consolidation) outperformed objectives at 9.6%, led by an acceleration of around 500bp driven by FilmArray® sales. In a volatile currency environment, reported sales growth came to 7.1%, held back by a negative currency effect of around €33 million, as well as the change in scope resulting primarily from the deconsolidation of bioTheranostics as of January 1, 2016.

Download [ www.biomerieux.com/sites/corporate/files/news-event-press-release/biomerieux_pr_sales_q4_2016.pdf ]

Record changed: 2017-02-09